--- title: "Nutriband shareholders approve proposals and expand board leadership" type: "News" locale: "en" url: "https://longbridge.com/en/news/274699852.md" description: "Nutriband held its 2026 Annual Meeting of Stockholders on January 24, 2026, where shareholders approved the election of seven directors, ratified the independent audit firm, and increased authorized preferred shares. The Board appointed two additional directors to enhance governance. The latest analyst rating for Nutriband (NTRB) is a Buy with a $15.00 price target, although Spark's AI Analyst rates it as Neutral due to mixed financial performance. Nutriband's market cap is $58.32M, with an average trading volume of 34,771." datetime: "2026-02-03T18:57:53.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/274699852.md) - [en](https://longbridge.com/en/news/274699852.md) - [zh-HK](https://longbridge.com/zh-HK/news/274699852.md) generator: "portal-rs" --- # Nutriband shareholders approve proposals and expand board leadership ### Claim 50% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Nutriband ( (NTRB) ) has provided an update. Nutriband held its 2026 Annual Meeting of Stockholders on January 24, 2026, in Orlando, Florida, where shareholders voted on director elections, auditor ratification, amendments to the company’s capital structure, and executive compensation matters. Shareholders elected seven directors to one-year terms, ratified Sadler, Gibb & Associates, LLC as the independent audit firm for fiscal 2025, and approved an amendment to increase the number of authorized preferred shares from 10,000,000 to 20,000,000, while also supporting advisory resolutions on executive pay and the frequency of future say-on-pay votes, and the Board subsequently appointed two additional directors, Alessandro Puddu and Viorica Carlig, adding financial, corporate advisory, and aviation industry expertise to the company’s governance structure. The most recent analyst rating on (NTRB) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Nutriband stock, see the NTRB Stock Forecast page. **Spark’s Take on NTRB Stock** According to Spark, TipRanks’ AI Analyst, NTRB is a Neutral. Nutriband’s overall stock score is driven by a strong corporate event with positive market reception, offset by challenging financial performance and valuation issues. The technical analysis provides mixed signals, suggesting cautious optimism. The potential for shareholder value enhancement through recent corporate actions improves the score despite underlying financial weaknesses. To see Spark’s full report on NTRB stock, click here. **More about Nutriband** **Average Trading Volume:** 34,771 **Technical Sentiment Signal:** Sell **Current Market Cap:** $58.32M See more data about NTRB stock on TipRanks’ Stock Analysis page. ### Related Stocks - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [NTRB.US](https://longbridge.com/en/quote/NTRB.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) ## Related News & Research - [“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z](https://longbridge.com/en/news/297407072.md) - [Grupa Azoty announces extraordinary shareholder meeting](https://longbridge.com/en/news/297635728.md) - [EverGen Infrastructure Reports Q2 2026 Results | EVGIF Stock News](https://longbridge.com/en/news/297122882.md) - [Biotech Stocks Facing FDA Decision In September 2026](https://longbridge.com/en/news/297065559.md) - [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**